EMPA-REG OUTCOME

Study / Research

The first major randomized placebo-controlled trial for SGLT2 inhibitors which showed a 38% reduction in cardiovascular death, heart failure, and renal failure.

Mentioned in 1 video

Videos Mentioning EMPA-REG OUTCOME

#134 - James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise

#134 - James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise

Peter Attia MD

The first major randomized placebo-controlled trial for SGLT2 inhibitors which showed a 38% reduction in cardiovascular death, heart failure, and renal failure.